Shigella isolates from the global enteric multicenter study inform vaccine development.
- Livio, Sofie
- Strockbine, Nancy A
- Panchalingam, Sandra
- Tennant, Sharon M
- Barry, Eileen M
- Marohn, Mark E
- Antonio, Martin
- Hossain, Anowar
- Mandomando, Inacio
- Ochieng, John B
- Oundo, Joseph O
- Qureshi, Shahida
- Ramamurthy, Thandavarayan
- Tamboura, Boubou
- Adegbola, Richard A
- Hossain, Mohammed Jahangir
- Saha, Debasish
- Sen, Sunil
- Faruque, Abu Syed Golam
- Alonso, Pedro L
- Breiman, Robert F
- Zaidi, Anita KM
- Sur, Dipika
- Sow, Samba O
- Berkeley, Lynette Y
- O'Reilly, Ciara E
- Mintz, Eric D
- Biswas, Kousick
- Cohen, Dani
- Farag, Tamer H
- Nasrin, Dilruba
- Wu, Yukun
- Blackwelder, William C
- Kotloff, Karen L
- Nataro, James P
- Levine, Myron M
DOIAbstract
BACKGROUND: Shigella, a major diarrheal disease pathogen worldwide, is the target of vaccine development. The Global Enteric Multicenter Study (GEMS) investigated burden and etiology of moderate-to-severe diarrheal disease in children aged <60 months and matched controls without diarrhea during 3 years at 4 sites in Africa and 3 in Asia. Shigella was 1 of the 4 most common pathogens across sites and age strata. GEMS Shigella serotypes are reviewed to guide vaccine development. METHODS: Subjects' stool specimens/rectal swabs were transported to site laboratories in transport media and plated onto xylose lysine desoxycholate and MacConkey agar. Suspect Shigella colonies were identified by biochemical tests and agglutination with antisera. Shi...
Add to ORKG